» Articles » PMID: 33813622

An Assessment of Intervention Thresholds for Very High Fracture Risk Applied to the NOGG Guidelines : A Report for the National Osteoporosis Guideline Group (NOGG)

Overview
Journal Osteoporos Int
Date 2021 Apr 4
PMID 33813622
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Guidelines for the assessment of fracture risk have begun to categorise patients eligible for treatment into high and very high risk of fracture to inform choice of therapeutic approach. The aim of the present study was to develop intervention thresholds based on the hybrid assessment model of NOGG.

Methods: We examined the impact of intervention thresholds in a simulated cross-sectional cohort of women age 50 years or more from the UK with the distribution of baseline characteristics based on that in the FRAX cohorts. The prevalence of very high risk using the hybrid model was compared with age-dependent thresholds used by the International Osteoporosis Foundation and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (IOF/ESCEO). The appropriateness of thresholds was tested based on the populations treated with anabolic agents.

Results: With an upper intervention threshold using the IOF/ESCEO criteria, 56% of women age 50 years or more would be characterised at very high risk. This compares with 36% using the IOF/ESCEO criteria and an age-specific intervention threshold over all ages. With an upper intervention threshold of 1.6 times the pre-existing intervention threshold, 10% of women age 50 years or more would be characterised at very high risk. The data from phase 3 studies indicate that most trial participants exposed to romosozumab or teriparatide would fall into the very high-risk category.

Conclusions: Proposals for FRAX-based criteria for very high risk for the NOGG hybrid model categorise a small proportion of women age 50 years or more (10%) in this highest risk stratum. The level of risk identified was comparable to that of women enrolled in trials of anabolic agents.

Citing Articles

A surrogate FRAX model for Mongolia.

Jaalkhorol M, Johansson H, Avirmed S, Dashtseren A, Bruyere O, Lorentzon M Arch Osteoporos. 2025; 20(1):27.

PMID: 39955704 PMC: 11830636. DOI: 10.1007/s11657-025-01501-y.


Romosozumab for the treatment of osteoporosis - a systematic review.

Makinen V, Solling A, McClung M, Langdahl B J Endocrinol Invest. 2024; 48(3):547-572.

PMID: 39487940 DOI: 10.1007/s40618-024-02469-1.


Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK.

Borgstrom F, Lorentzon M, Johansson H, Harvey N, McCloskey E, Willems D Osteoporos Int. 2024; 35(12):2183-2193.

PMID: 39365433 DOI: 10.1007/s00198-024-07251-w.


[Osteoporosis-Definition, risk assessment, diagnosis, prevention and treatment (update 2024) : Guidelines of the Austrian Society for Bone and Mineral Research].

Dimai H, Muschitz C, Amrein K, Bauer R, Cejka D, Gasser R Wien Klin Wochenschr. 2024; 136(Suppl 16):599-668.

PMID: 39356323 PMC: 11447007. DOI: 10.1007/s00508-024-02441-2.


Performance of the Brazilian Fracture Assessment Risk Tool (FRAX) model and the age-dependent intervention thresholds according to National Osteoporosis Guideline Group (NOGG) guidelines on fracture prediction in community-dwelling older adults: the....

Freitas T, Olalla L, Machado L, Figueiredo C, Takayama L, Caparbo V Arch Osteoporos. 2024; 19(1):59.

PMID: 38990403 DOI: 10.1007/s11657-024-01417-z.